Table 2. Salivary IgG antibody levels (GMC; ng/ml) in children after 2 doses, 2+1-doses of PCV7 or no PCV7 vaccinations (controls) at the age of 12 and 24 months.

	12 months				24 months
	Controls	2-dose	2+1-dose		Controls	2-dose	2+1-dose
Serotype	n = 60	n = 54	n = 63	p-Values	n = 55	n = 58	n = 62	p-Values
4	1.8	11.3	124.0	α, β, γ	1.5	6.0	14.8	α, β, γ
6B	4.4	12.7	188.2	α, β, γ	7.1	40.4	67.0	β, γ
9V	2.6	18.7	177.9	α, β, γ	2.7	11.8	34.3	α, β, γ
14	3.1	49.7	360.3	α, β, γ	3.2	15.7	52.3	α, β, γ
18C	1.1	11.5	137.3	α, β, γ	2.0	8.8	19.0	α, β, γ
19F	11.2	33.8	147.2	α, β, γ	19.7	72.3	85.7	β, γ
23F	1.2	8.2	112.4	α, β, γ	2.0	12.8	39.7	α, β, γ
1	4.6	3.0	3.7		4.3	4.1	5.7
3	1.2	1.3	0.7		1.0	1.4	1.5
5	8.6	7.3	9.1		11.2	10.7	12.9
7F	5.1	3.3	3.5		4.2	3.1	5.3

α p-Values<0.05; 2+1 vs. 2-dose schedule.

β p-Values<0.05; 2+1-dose vs. controls.

γ p-Values<0.05; 2-dose vs. controls.

Calculated using log transformed unpaired t test, p-values are 2 sided.